Alpenglow hits the track as Alpine doubles down on hydrogen; new V6 engine is in the works
Alpine has unveiled the Alpenglow Hy4, a hydrogen-combustion supercar that will be used to develop the technology for future road and track cars. An evolution of the Alpenglow concept shown two years ago, it tomorrow makes its dynamic debut at Spa-Francorchamps in Belgium as a showcase of the performance potential of the emerging technology. It is powered by a new turbocharged 2.0-litre four-cylinder engine said to be unrelated to the A110’s. Hydrogen is drawn from three tanks, each carrying 2.
Alpine said it is “paying close attention” to such regulation changes across motorsport. The brand also suggested that the V6 could even be bound for its future road cars. Bruno Famin, vice-president of Alpine Motorsports, said: “As part of our active participation in decarbonising motorsports, we see the hydrogen internal combustion engine as an extremely promising solution.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Updated Alpine Alpenglow Concept To Lap Spa-Francorchamps Next MonthThe dramatic concept is powered by a combustion engine fueled by hydrogen
Read more »
Alpine to run hydrogen-combustion supercar at Spa next monthAlpenglow prototype aims to prove that hydrogen-fuelled engines can "enhance driving pleasure" tenfold
Read more »
Alpenglow concept returns as hydrogen-powered Hy4Four-cylinder and 340hp for now, but Alpine is also working on a new V6...
Read more »
Alpine hypercar concept to run hydrogen engine at SpaLe Mans may soon have a class for hydrogen-powered cars, and Alpine's Alpenglow concept may provide a clue of what a race car for the class will be like.
Read more »
Stocks making the biggest premarket moves: Nike, CarMax, Robinhood, Alpine Immune Sciences and moreThese are the stocks posting the largest moves in the premarket.
Read more »
Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune dealVertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday.
Read more »